Merck Lowers First Quarter Outlook (MRK)
Drug maker Merck & Co. Inc. (NYSE: MRK) this morning lowered its first quarter non-GAAP EPS estimate to $0.95-$0.98, well below the previous consensus estimate of $1.03. For the full-year, Merck expects non-GAAP EPS of $3.75-$3.85, compared with a consensus…
Drug maker Merck & Co. Inc. (NYSE: MRK) this morning lowered its first quarter non-GAAP EPS estimate to $0.95-$0.98, well below the previous consensus estimate of $1.03. For the full-year, Merck expects non-GAAP EPS of $3.75-$3.85, compared with a consensus estimate of $3.81.
The company also said that 2012 revenues βto be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent.β Merckβs calculations are based on an exchange rate of $1.31/euro.
The euro/dollar exchange rate is also expected to have a negative impact of -1% to -2% on first quarter earnings. Full-year sales are expected to get whacked by -2% to -3% as a result of the euro/dollar exchange rate.
Merckβs shares are down more than -1% in the pre-market, at $38.02 in a 52-week range of $29.47-$39.43.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
